UKi2S is an early-stage venture capital firm that invests in innovations emerging from the UK's publicly funded science and knowledge base, specializing in engineering biology, defence & security, fusion energy, and space. Their strategy involves providing pre-seed and seed capital, typically between £100k and £500k, with the aim of facilitating sustainable growth, enhancing societal health and security, and delivering economic gains.
50% of their portfolio is in Biotech & Life Sciences. Their most common stage is seed (90% of deals). Average disclosed round size is $4.5M (across 9 rounds with reported amounts).
Portfolio
10
Fund Size
$102M
Top Stage
Seed
Last 12 Mo
5
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ternary Therapeutics | Seed | $4.1M | Mar 2026 |
 CamGene Therapeutics | Seed | — | Nov 2025 |
| AAstut | Seed | $1.8M | Oct 2025 |
 SugaROx | Seed | $1.2M | Aug 2025 |
 Spaceflux | Seed | $6.1M | Jul 2025 |
| IiFAST Diagnostics | Seed | $5.9M | Nov 2024 |
 Antiverse | Seed | $4.2M | Oct 2024 |
| SSOLASTA Bio | Series A | $14M | Sep 2024 |
 Mirico | Seed | $2M | Jun 2024 |
| SSOLASTA Bio | Seed | $1.5M | Aug 2021 |
Top Co-Investors
Forbion1 shared
Cavallo Ventures1 shared
Rubio Impact Ventures1 shared
Scottish Enterprise1 shared
Cambridge Enterprise1 shared
Parkwalk Advisors1 shared
KHP Ventures1 shared
OKG Investments1 shared
Kadmos Capital1 shared
Daphni1 shared
Future Planet Capital1 shared
Foresight Ventures1 shared
New Climate Ventures1 shared
Last updated: 21 April 2026